A genetically engineered mouse initially designed to explore muscle repair mechanisms instead helped University of Iowa scientists understand how a certain type of calcium channel helps coronary ...
CHARLOTTESVILLE, Va. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cavion, Inc., a clinical stage biotechnology company developing novel therapeutics for neurological diseases, announced today that their first ...
Phase II trial of triple-receptor tyrosine kinase receptor inhibitor nintedanib (BIBF 1120) in recurrent high-grade gliomas. This is an ASCO Meeting Abstract from the 2013 ASCO Annual Meeting I. This ...
Neurocrine's $45M bet goes 0 for 2 with rare epilepsy flop following negative essential tremor trial
Neurocrine Biosciences’ $45 million rare pediatric epilepsy bet has fallen at an early clinical hurdle. Thirty months after licensing the selective T-type calcium channel inhibitor, the biotech has ...
Work at Praxis Precision Medicines Inc. has led to the identification of new compounds comprising an azaspiroheptane and acting as T-type calcium channel blockers, particularly voltage-dependent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results